Video

Eleanor Perfetto, PhD, MS, Discusses How HEOR Departments Use Comparative Effectiveness Research

Comparative effectiveness research (CER) collaborative tools can benefit pharmaceutical companies in a variety of ways.

Comparative effectiveness research (CER) collaborative tools can benefit pharmaceutical companies in a variety of ways. Eleanor Perfetto, PhD, MS, professor, pharmaceutical health services research, School of Pharmacy, University of Maryland, for instance, suggests that CER can be utilized in internal training programs as well as in making research studies translatable to managed care organizations and their leaders.

“For the most part, the responsibilities within the company are to get a drug approved, and that relies heavily on a randomized control trial design. Now that we have decision-makers who are out there looking at aspects beyond what the FDA would be looking for when a drug is being approved, they’re looking for some of the endpoints the FDA would consider secondary,” says Dr Perfetto.

She adds that the role of HEOR groups within pharmaceutical organizations will continue to grow and evolve.

Related Videos
Screenshot of an interview with Evangelia Vlachou, MD
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health
Screenshot of an interview with Barry Goy, MD
Gladys Antelo Allen
Dr Michael Bernstein
Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine
Debra Patt, MD, PhD, MBA, MPH
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Mikkael Sekeres, MD
Kim Newcomer, director of volunteers, Colorectal Cancer Alliance
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo